FDA — authorised 17 October 2023
- Application: NDA217836
- Marketing authorisation holder: ORASIS PHARMS
- Local brand name: QLOSI
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
🇺🇸 CSF-1 in United States
FDA authorised CSF-1 on 17 October 2023
Marketing authorisation
Other Immunology approved in United States
Frequently asked questions
Is CSF-1 approved in United States?
Yes. FDA authorised it on 17 October 2023.
Who is the marketing authorisation holder for CSF-1 in United States?
ORASIS PHARMS holds the US marketing authorisation.